Journal of Developing Drugs最新文献_第5页

6-Gingerol is the most Potent Anticancerous Compound in Ginger (Zingiber officinale Rosc.) 6-姜辣素是生姜中最有效的抗癌化合物。

Journal of Developing Drugs Pub Date : 2017-01-26 DOI: 10.4172/2329-6631.1000167

K. M., Shylajab Mr, Nazeemc Pa, Babu T

{"title":"6-Gingerol is the most Potent Anticancerous Compound in Ginger (Zingiber officinale Rosc.)","authors":"K. M., Shylajab Mr, Nazeemc Pa, Babu T","doi":"10.4172/2329-6631.1000167","DOIUrl":"https://doi.org/10.4172/2329-6631.1000167","url":null,"abstract":"Cancer is one of the most deadly diseases in the world, which is caused due to uncontrolled growth of cells or malfunction of genes that control normal cell growth and division. Because of high death rate associated with cancer and because of serious side effects of chemotherapy and radiation therapy, many cancer patients seek alternative complementary methods of treatment. Ginger (Zingiber officinale Rosc.) is an important spice crop with immense medicinal properties and health beneficial effects. All the ginger ligands showed good interaction with the selected targets but based on ADME/Toxicity analysis 6-gingerol was superior with respect to absorption, solubility, and less neurotoxic effect as compared to other ginger ligands. 6-gingerol was also found cytotoxic to all the three cancer cells lines were studied. The cytotoxicity increased with increase in concentration of 6-gingerol. The IC50 values recorded for different cancer cell lines, 24 h. after treatment (100 µM for HCT15, 102 µM for L929 and 102 µM for Raw 264.7) showed uniform cytotoxicity in the three cell lines studied. The study highlights the potential of 6-gingerol for drug development against cancer.","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"16 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2017-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82702781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 32

Prevalence and Clinical Significance of Potential Drug-Drug Interactions at Ayder Referral Hospital, Northern Ethiopia 埃塞俄比亚北部艾德尔转诊医院潜在药物相互作用的患病率及临床意义

Journal of Developing Drugs Pub Date : 2017-01-01 DOI: 10.4172/2329-6631.1000179

Teshager Aklilu Yesuf, A. Belay, Eskinder Ayalew Sisay, Zigbey Brhane Gebreamlak

{"title":"Prevalence and Clinical Significance of Potential Drug-Drug Interactions at Ayder Referral Hospital, Northern Ethiopia","authors":"Teshager Aklilu Yesuf, A. Belay, Eskinder Ayalew Sisay, Zigbey Brhane Gebreamlak","doi":"10.4172/2329-6631.1000179","DOIUrl":"https://doi.org/10.4172/2329-6631.1000179","url":null,"abstract":"Introduction: Clinically significant drug-drug interactions reduce effectiveness of drugs or cause fatal adverse events. Although harmful drug interactions are preventable, clinicians’ recognition and detection of drug interactions is not optimal. Objective: To assess prevalence, clinical significance and factors associated with potential drug-drug interactions at medical ward of Ayder Referral Hospital, Ethiopia. Methods: A cross-sectional study was conducted to determine potential drug-drug interactions. A total of 204 patients’ medical records were analyzed for drug-drug interaction using Micromedex drug interaction software. Data were analyzed using SPSS version 16. Results: We identified 135 interacting-combinations in a total of 266 potential drug-drug interactions (pDDIs) with a mean of 1.3 pDDIs per patient. Of these, 30.1% and 53.7% of patients had at least one major and one moderate pDDIs respectively. The most common pDDIs involved were concurrent use of clarithromycin with simvastatin, aspirin with heparin and dexamethasone with rifampin which have contraindication, major and moderate severity respectively. There was significant association of occurrence of pDDIs with polypharmacy (p<0.01). Conclusion: Potential drug-drug interactions were common at the medical ward of our hospital.","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"1 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83252079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Does the Boson Peaks Exist in Small Neutral Gold Clusters 小中性金团簇中存在玻色子峰吗

Journal of Developing Drugs Pub Date : 2017-01-01 DOI: 10.4172/2329-6631.1000178

K. Vishwanathan, M. Springborg

引用次数: 1

Design and Development of Fast Dissolving Tablet of Gliclazide 格列齐特速溶片的设计与研制

Journal of Developing Drugs Pub Date : 2017-01-01 DOI: 10.4172/2329-6631.1000177

sharad Kondiba Kamble, S. ShindeSunita

{"title":"Design and Development of Fast Dissolving Tablet of Gliclazide","authors":"sharad Kondiba Kamble, S. ShindeSunita","doi":"10.4172/2329-6631.1000177","DOIUrl":"https://doi.org/10.4172/2329-6631.1000177","url":null,"abstract":"In the present study, Gliclazide is a second-generation sulfonyl urea derivative used to treat non-insulin dependent diabetes mellitus. The drug has been classified as class-II drug according to biopharmaceutical classification system having low solubility and high permeability. So, an attempt was made to enhance the solubility of gliclazide by solvent evaporation technique. A significant enhancement of gliclazide dissolution rate will be obtained using by using suitable techniques. In this PVP-k30, polyethylene glycol and soluplus were mixed with the drug in different ratios (1:1, 1:3) and prepare P1, P2, PE1, PE2, S1 and S2 solid dispersion batches. The optimized solid dispersions P1 were further kneaded with suitable proportions of super disintegrants such as; Cross carmellose and Sodium starch glycolate. Dissolution profile will show decrease amount of drug release at specified time. DSC as well as X-ray diffraction showed reduced drug crystallinity in SDs. Scanning electron microscopy and particle size analysis revealed significant decreased particle size of the drug in SDs. FT-IR spectroscopy demonstrated no detectable interactions between the drug and excipients. On that the P1 batch will be consider for eight different fast dissolving tablets Preparation. The prepared FDT’s were evaluated for various parameters like disintegration time, wetting time, drug content, in vitro drug release study etc. and shows the satisfactory result. The formulation of F-4 containing cross carmellose sodium (5%) showed better result in disintegration time 11 sec. and maximum in vitro drug release of 99.89% at the end of 40 minutes.","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"48 1","pages":"1-13"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78209408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

The Relationship of Polymorphism of RFC-I Gene on Methotrexate Serum Level and Related Toxicity in Pediatric Acute Lymphoblastic Leukemia 小儿急性淋巴细胞白血病rfc - 1基因多态性与甲氨蝶呤血清水平及相关毒性的关系

Journal of Developing Drugs Pub Date : 2017-01-01 DOI: 10.4172/2329-6631.1000180

F. Zaker, S. Ansari, B. Toosi, M. Sayadi, H. Sharafi

{"title":"The Relationship of Polymorphism of RFC-I Gene on Methotrexate Serum Level and Related Toxicity in Pediatric Acute Lymphoblastic Leukemia","authors":"F. Zaker, S. Ansari, B. Toosi, M. Sayadi, H. Sharafi","doi":"10.4172/2329-6631.1000180","DOIUrl":"https://doi.org/10.4172/2329-6631.1000180","url":null,"abstract":"Introduction: Methotrexate is one of the most effective agents in chemotherapy regimens for childhood ALL. However, methotrexate has remarkable side effects, which causes complications in various tissues and organs of some patients under treatment of this drug. It is proved that genetic factors can determine methotrexate toxicity. The aim of this study is to evaluate the effect of RFC-I A80G polymorphism on toxicity and serum level of methotrexate in children affected by acute lymphoblastic leukemia. Methods: A80G polymorphism of RFC-I was genotyped with PCR-RFLP method in 69 ALL patients treated with methotrexate. The relation between RFC-I genotypes and serum level of methotrexate and toxicity were evaluated using HPLC method and common terminology criteria for adverse events (CTCAE) respectively. Results: In this study, frequency of allele A for A80G polymorphism was 42.8% in patients who were studied. In consolidation phase, allele A frequency in patients with hepatotoxicity was higher than patients with no hepatic event (P=0.03, OR=2.32, 95% CI=1.10-4.98). Nevertheless, there were not any association between the other types of toxicity and RFC-I genotypes. Also, there was no association between A80G genotypes and the serum level of methotrexate. Conclusion: Based on the obtained results, we concluded that allele A of A80G polymorphism of RFC-I gene is a risk factor for methotrexate hepatotoxicity in consolidation phase and the A80G polymorphism can be utilized for prediction of methotrexate toxicity and dose adjustment.","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"1 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88080097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Ternary Amorphous Solid Dispersions 三元非晶固体分散体

Journal of Developing Drugs Pub Date : 2017-01-01 DOI: 10.4172/2329-6631.1000181

Dev Prasad, J. Lande, H. Chauhan, Harsh Chauhan

引用次数: 1

A Review of Plant Sulfated Polysaccharides and their Relations with Anticoagulant Activities 植物硫酸多糖及其与抗凝血活性的关系研究进展

Journal of Developing Drugs Pub Date : 2016-12-12 DOI: 10.4172/2329-6631.1000166

Oliveira Rcr, Almeida Rr, Gonçalves Ta

引用次数: 15

Effect of AF-Anti Fungal Cream on Stratum Corneum and its Importance in Treating Cutaneous Mycoses af -抗真菌乳膏对角质层的作用及其在皮肤真菌病治疗中的意义

Journal of Developing Drugs Pub Date : 2016-11-22 DOI: 10.4172/2329-6631.1000163

Aruna., Amrurthavalli Gv, G. Rajagopal

引用次数: 1

Ivabradine for the Management of Chronic Stable Angina: Should it beconsidered? 伊伐布雷定治疗慢性稳定型心绞痛:应该考虑吗?

Journal of Developing Drugs Pub Date : 2016-11-14 DOI: 10.4172/2329-6631.1000e149

Amy Wang

{"title":"Ivabradine for the Management of Chronic Stable Angina: Should it beconsidered?","authors":"Amy Wang","doi":"10.4172/2329-6631.1000e149","DOIUrl":"https://doi.org/10.4172/2329-6631.1000e149","url":null,"abstract":"Angina, or chest pain, often occurs when oxygen demand of the heart exceeds oxygen supply. The imbalance between oxygen supply and demand may be due to blockage in the coronary arteries, arterial vasospasm, or myocardial dysfunction [1]. Chronic stable angina (CSA) is described as having chest pain due to exertion (such as exercise or stress), or chest pain that is relieved by rest or administration of nitroglycerin [2]. Conventional therapies for CSA includes negative inotropes, such as beta blockers (BB) and calcium channel blockers (CCB), or vasodilators, such as nitroglycerin (NTG). Unfortunately, BBs and CCBs have been associated with adverse effects such as fatigue and severe bradycardia, while use of NTG may lead to severe hypotension and headache [1]. Ivabradine is a new class of medication, and works by blocking the If current in the sinoatrial node to slow down heart rate. By lowering the heart rate, it decreases workload and oxygen demand for the heart [3]. In the European Union, ivabradine was approved for the management of symptoms on CSA in patients with history of coronary artery disease (CAD), or for the management of heart failure (HF). Prior to initiating ivabradine for the management of CSA, patients must have heart rates of at least 70 beats per minute, and either cannot tolerate beta blocker therapy, or whose symptoms are not adequately controlled by beta blocker therapy alone [4]. In the United States, ivabradine is only approved for the management of HF, but not for CSA [3].","PeriodicalId":15589,"journal":{"name":"Journal of Developing Drugs","volume":"49 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2016-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85588470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological Options Beyond Proton Pump Inhibitors in Children with Gastroesophageal Reflux Disease 儿童胃食管反流病质子泵抑制剂以外的药物选择

Journal of Developing Drugs Pub Date : 2016-10-18 DOI: 10.4172/2329-6631.1000161

C. Armano, L. Fumagalli, A. Ripepi, A. Moretti, F. Macchi, A. Scolari, S. Salvatore

引用次数: 0